Low PSA on ADT: Still Prognostic in New Treatment Era Low PSA on ADT: Still Prognostic in New Treatment Era

In metastatic prostate cancer, a study from 2006 established that a low PSA at 7 months after start of androgen deprivation therapy was associated with significantly longer survival. But times and treatments change.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news